in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
At about the same time, seminal observations implicating blood-vessel growth in intraocular disorders ... that a diffusible factor (named afterward 'factor X') could be responsible not only ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...
To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...
The researchers appear to believe that 2dDR up-regulates vascular endothelial growth factor required for new hair growth.
Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...
Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...